Former Portfolio Companies

Second Genome has built a novel microbiome technology platform, resulting in a pipeline of drug discovery programs, including several microbiome-derived proteins, peptides and metabolites, with applications across gastrointestinal disease, immuno-oncology, inflammation and metabolic diseases. 

South San Francisco